opathy and myocarditis were considered. She was treated with corticosteroids commenced at 50 mg daily, to which she reKeywords: antidepressant drug, venlafaxine; cytochrome P450; druginduced pneumonitis; heart failure sponded well (Table 1 ). The corticosteroid dose was tapered every 2 days by 10 mg and finally stopped 10 days after initiation.
sponded well (Table 1 ). The corticosteroid dose was tapered every 2 days by 10 mg and finally stopped 10 days after initiation.
The number of drugs that have been shown to damage the Thereafter, her clinical condition deteriorated. As no explanarespiratory system continues to increase (1, 2) . The clinical tion for the cardiopulmonary disease could be established and pattern is diverse. Venlafaxine is an antidepressant with a sarcoidosis was considered, she was referred to the Sarcoidosis unique chemical structure. It inhibits significantly reuptake 
CASE 1
her general physician, commenced 2 months before symptom presentation and continued during admission (the patient's own A 21-year-old woman was admitted to her local hospital 2 initiative without mentioning as she thought it was harmless). months before referral to the Sarcoidosis Management Center
With the suspicion of a drug-induced hypersensitivity pneumonia, venlafaxine was stopped and glucocorticoid treatment restarted (40 mg daily, gradually tapered to cessation over 2 weeks 
CASE 2
June 2000, demonstrated the appearance of new ground glass shadowing in both lungs, especially the left lower lobe. Lung A 62-year-old sales manager presented with a 6-week history of function tests showed a deterioration since May 2000 (Table 1) . exertional dyspnea, a dry cough, and fever. He had a diagnosis Echocardiography demonstrated significant reduction in LV of ischemic heart disease following an anterior myocardial infunction (May 2000: LV end-diastolic diameter, 5.2 cm; endfarction 30 years previously and chronic atrial fibrillation for systolic diameter, 4.9 cm; November 2000: end-diastolic diamewhich he was anticoagulated and prescribed digoxin. Between ter, 6.4 cm; end-systolic diameter, 5.0 cm). 1995 and 1999 he received amiodarone (200 mg daily). In March
The patient was treated with broad-spectrum antibiotics, ve-1999, he was referred to the respiratory clinic because of a cough rapamil and digoxin, and oxygen, and anticoagulation was adand an abnormal CXR revealing infiltrates in the right lower justed. The differential diagnosis included recurrence of bronzone. Transbronchial biopsy demonstrated adenocarcinoma choalveolar cell carcinoma, or a drug-induced infiltrative lung compatible with bronchoalveolar cell carcinoma. He underwent disease (DI-ILD). The timing of the presentation soon after right lower lobectomy in October 1999; amiodarone was stopped starting the antidepressant drug venlafaxine, together with its pattern on HRCT, favored venlafaxine as the cause. Venlafaxine was stopped. Empirical steroid treatment was deemed too hazardous in the context of a persisting febrile illness, and raised inflammatory indices (C-reactive protein Ͼ 100 mg/L). During the next 24 hours, he developed hypotension and O 2 desaturation. His condition deteriorated and despite inotropic support, he progressed to multiple organ failure and died. Autopsy revealed large pulmonary emboli, focal ischemia and superficial ulceration of the colonic mucosa, and heart failure. The lungs showed evidence of local recurrence of carcinoma on the right. On the left, there were features of established interstitial fibrosis and florid organizing pneumonia without eosinophils, but no features of lymphocytic interstitial pneumonia or carcinoma.
DISCUSSION
The similar clinicopathologic picture and temporal association with drug initiation in the cases presented strongly suggest the development of venlafaxine-induced noneosinophilic interstitial pneumonia and cardiac failure. Such simultaneous association has not been reported previously. In the first patient, withdrawal of the drug together with steroid treatment led to complete case, the temporal relationship and the pattern on HRCT and induced disease may be complicated by the fact that the symptoms are often nonspecific, the patient's underlying disease may be responsible for cardiopulmonary abnormalities, and the use of multiple drugs reduces the chances of identifying the offending agent (1, 2, 11) . In general, the recognition of DI-ILD has become an increasingly important area in pulmonary disorders. Clinical presentation of DI-ILD varies and to relate lung disease with a drug, there must be a temporal relationship, appropriate clinical presentation, and ideally, improvement with discontinuation of the drug. Drug-induced reactions can cause any known pattern of lung histology. There are no specific tests; rechallenge is unlikely to be helpful and is generally regarded to be dangerous.
Venlafaxine belongs to a new generation of antidepressants inhibiting the reuptake of serotonin/noradrenaline (12). The exact mechanism of lung injury is uncertain for most DI-ILDs (8, 12) . DI-ILD is an established, albeit infrequent complication of the serotonin reuptake inhibitors such as fluoxetine (7, 8, 13). Increased pulmonary capillary leakage, noncaseating giant cell granulomas, interstitial pneumonia, and nonnecrotizing vasculitis have been described (14, 15) . Various cardiovascular side effects reported with venlafaxine include vascular headache, angina pectoris, hypotension, but also hypertension and syncope (16, 17) . Less commonly, sinus bradycardia, first-degree atrioventricular block, bundle branch block, and even sudden death have been reported, suggesting venlafaxine is a possible proarrhythmic agent. The cases described had documented evidence of deterioration in ventricular function coincident with the use of venlafaxine and, in Case 1, an improvement on withdrawal. Direct toxic effect or hypersensitivity is likely.
The risk for development of DI-ILD, cardiopulmonary effects, and clinical patterns vary depending on a variety of host and drug factors (2) . The lung is a target for toxicity because of its biotransformation pathways and/or pulmonary drug accumu- contains several enzymatic pathways capable of xenobiotic metabolism, it is generally agreed that the cytochrome P (CYP) superfamily of enzymes is the main system catalyzing the oxidative metabolism and metabolic activation of most toxins and autopsy (organizing pneumonia) were consistent with a DI-ILD.
drugs. However, knowledge of the functional activities and cellAn association of venlafaxine use and the reported clinical picspecific localization of the pulmonary CYP forms is still incomture was a strong possibility. Moreover, amiodarone likely played plete (11). There is interindividual variation in the metabolic no role in the final illness, having been stopped 17 months prehandling of drugs. Host factors including genetic polymorphisms viously. The list of drugs implicated in lung injury has grown of the CYP gene(s) may be important determinants of susceptirapidly during the last decades (1, 2) . The exact mechanism of bility to adverse drug effects (10, 11). Increased plasma concenlung injury is uncertain for most drugs. As venlafaxine reduces trations of venlafaxine can be observed not only after overdose serotonin reuptake-like anorexic agents-a possible associaadministration of the drug but also because of decreased cleartion with pulmonary hypertension has been considered (8) . It ance in some subjects (14) . Venlafaxine is metabolized by an is unlikely to be a direct effect and is probably a result of biotransisoenzyme of the cytochrome P450 system (CYP2D6) (14) . In formation of the drug in the lung to reactive metabolites and/ particular, CYP2D6 may manifest phenotypically as slow or or oxygen species that damage lung cells (8) . The lung is the rapid metabolizers (18, 19). Administration of venlafaxine to target for this toxicity because of accumulation of the drug in poor metabolizers places them at risk of accumulation of the the lung and/or the presence of a specific biotransformation drug to toxic concentrations (14) . Adverse drug reactions are pathway in the lung.
possible if the drug is an inhibitor of CYP isoenzymes and disIn hypersensitivity pneumonitis, as in DI-ILD, the first stage rupts enzyme function. Furthermore, genetic differences may consists of an inflammatory process that evolves, over years, affect the function of P450 enzymes, resulting in a related change inevitably toward pulmonary fibrosis (1, 2, 9) . Presumably, in in drug clearance and production of oxygen species (18, 19). some cases the presence of a fibrotic process reflects presentation Until phenotyping becomes widely available, careful therapeutic at a later stage occurring after a previously overlooked allergic monitoring and follow-up should determine individualized dosage. inflammation. Interestingly, Hubbard and coworkers found an
In the second patient, it is possible that aberrant cytochrome association between cryptogenic fibrosing alveolitis and tricyclic P450 metabolism predisposed him to interstitial pneumonitis antidepressant exposure (10). Therefore, for clinicians an early when exposed to venlafaxine together with verapamil. Drugs diagnosis of such pneumonitis is important because early drug with a narrow therapeutic window and long half-life may cause cessation will reduce significantly the risk of irreversible fibrosis serious toxicity especially in the case of interaction with drugs with affinity for the same cytochrome P450 isoenzyme (14) . Also, (2, 10). Even though not uncommon, the diagnosis of drug-
